Terns Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Hello, everyone, and welcome to Oppenheimer's 33rd Annual Healthcare Conference. I'm Jay Olson, one of the biotech analysts at Oppenheimer. And I want to thank you all for joining us here today. It's a pleasure to welcome Terns Pharmaceuticals to our conference, and it's an honor to introduce Erin Quirk, Head of R&D; and Mark Vignola, Chief Financial Officer. Thank you both so much for joining us today.
I'm going to turn it over to you for your presentation, and then I'll come back for some Q&A afterwards.
Sounds great. So thank you, Jay and for the entire Oppenheimer team for the opportunity to present here today and tell you a little bit about the advancements we're making at Terns in serious metabolic and oncology diseases. I'd invite you to look to our website for our forward-looking statements and disclaimers as usual.
To provide an overview of turns on a one-pager, we are a publicly traded
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |